CRISPR Gene Therapy Casgevy Secures English Funding, Highlighting Broader Promise of Gene Editing for Rare Diseases

CRISPR Gene Therapy Casgevy Secures English Funding, Highlighting Broader Promise of Gene Editing for Rare Diseases

A significant development in the world of gene therapy has unfolded in England, with Vertex’s CRISPR/Cas9 gene therapy, Casgevy, securing funding. While Casgevy is approved for specific blood disorders, this milestone holds broader implications for the inherited retinal disease (IRD) community, demonstrating the increasing viability and accessibility of groundbreaking gene-editing technologies. The progress in securing funding for such advanced therapies paves the way for future treatments for a range of genetic conditions, including those affecting vision.

Casgevy, developed by Vertex Pharmaceuticals in collaboration with CRISPR Therapeutics, is a one-time gene-edited cell therapy that utilizes CRISPR/Cas9 technology. It is approved for patients aged 12 and older with transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD) who experience recurrent vaso-occlusive crises. The therapy works by modifying a patient's own blood-forming stem cells to enable them to produce healthy red blood cells, specifically by increasing the production of fetal hemoglobin. This approval marks a